Labelled chemical probes for demonstrating direct target engagement in living systems. by Prevet, H & Collins, I
1 
 
Labelled chemical probes for demonstrating direct target engagement in 
living systems 
 
Hugues Prevet* and Ian Collins 
Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London 
SW7 3RP, U.K. 
 
 
*Corresponding author: hugues.prevet@icr.ac.uk  
  
2 
 
Abstract 
 
Demonstrating target engagement in living systems can help drive successful drug discovery. 
Target engagement and occupancy studies in cells confirm direct binding of a ligand to its 
intended target protein and provide the binding affinity. Combined with biomarkers to 
measure the functional consequences of target engagement, these experiments can increase 
confidence in the relationship between in vitro pharmacology and observed biological effects. 
In this review, we focus on chemically and radioactively labelled probes as key reagents for 
performing such experiments. Using recent examples, we examine how the labelled probes 
have been employed in combination with unlabelled ligands to quantify target engagement in 
cells and in animals. Finally, we consider future developments of this emerging methodology. 
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1. Introduction 
Having the confidence that the observed biological effect is due to a ligand engaging its 
intended target in a relevant cellular model is one of the biggest challenges of drug discovery. 
Indeed, understanding target engagement has been described as one of four strategic pillars 
needed to drive successful drug discovery programs [1]. Monitoring target engagement is 
essential early in drug discovery to link target modulation with cell efficacy (Figure 1). It can 
also be crucial for better understanding the reasons of potential failure during later preclinical 
studies, or even in clinical trials [2]. Drug discovery often relies on target-based assays 
involving isolated or purified recombinant proteins to establish structure-activity 
relationships (SARs) for new compounds and to optimise their potency. However, the 
properties of target-based in vitro assays are different to the more complex intracellular 
environment of cell-based assays which might result in a decrease in potency, termed “cell 
drop off” [3], and potentially lead to misleading conclusions regarding the origin of the 
phenotype observed. For example, such differences may include changes in small molecule 
substrate or cofactor concentrations between in vitro assays and cells that affect ligand 
potency for the target (e.g. ATP competitive kinase inhibitors [4]) or the complexation of 
target proteins with partner biomolecules in cells that change the affinities of ligands and are 
not recapitulated in the in vitro assays. 
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Figure 1: Target-based assay vs. cell-based assay - the utility of target engagement 
experiments early in drug discovery 
Target engagement refers to the capacity of a ligand to interact with its target in living 
systems. It can be either demonstrated directly (assessing the binding of the ligand to its 
target protein) or deduced from downstream pathway effects with proximal biomarkers (e.g. 
assessing substrate-product changes or post-translational modifications, such as 
phosphorylation) [5]. However, such substrate-product transformations may be controlled by 
several pathways and thus changes induced by the ligand binding might not be robustly 
attributable to only one target [5]. This review is focused on direct target engagement 
experiments that provide the most immediate evidence and quantification of ligand-target 
association in living systems. 
Direct target engagement experiments can be carried out using distinct strategies [6]. Some of 
these require functionalisation or modification of the target protein, such as fluorescence 
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resonance energy transfer (FRET) or bioluminescence resonance energy transfer (BRET) 
technologies. However, functionalisation of a target protein might alter its endogenous 
expression and activity and therefore the result observed in such cases might display reduced 
relevance to the unmodified system. Alternatively, the cellular thermal shift assay (CETSA) 
is a powerful method for monitoring the binding of unlabelled ligands to endogenous proteins 
in cell lysates [7]. This label-free technology assesses the protein thermal stability following 
ligand binding. However, not all proteins show a detectable thermal stabilisation upon ligand 
binding [8]. Hence, new methods have recently emerged to demonstrate direct target 
engagement of unlabelled ligands with endogenous proteins at cellular or sub-cellular 
resolution. These methods rely on functionalised reporter ligands that, for convenience, we 
refer to here as labelled chemical probes. Using selected examples from recent literature, we 
will examine how labelled chemical probes have been used to demonstrate direct target 
engagement in living systems. Most examples described to date involve cell lines, but 
increasingly direct target engagement in animal models has been explored, and PET imaging 
of target engagement in tissues using radiolabelled chemical probes is clinically applicable. 
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2. The distinction between pharmacological tools and labelled chemical probes 
2.1. Pharmacological tools 
Although both pharmacological tools and labelled chemical probes have a major place in 
drug discovery, there are differences regarding their design and applicability. 
Pharmacological tools are of particular importance in the chemical biology field. They are 
typically defined as small molecules able to modulate a specific protein’s function in order to 
interrogate the role(s) of the targeted proteins in living systems such as cells, tissues and 
animals. Complementary to genetic tools such as RNAi and CRISPR, pharmacological tools 
can be used for elucidating the biological mechanisms leading to a specific phenotypic effect 
and therefore are key reagents for target validation in drug discovery [9-11]. Typically, 
pharmacological tools have to be comprehensively optimised and characterised to avoid 
generating misleading results when they are used as specific reagents to perturb biological 
systems [10, 11]. Data sources such as The Chemical Probes Portal [12] and Probe Miner 
[13] have been established to support the selection of high quality of pharmacological tools. 
The current consensus for developing high-quality pharmacological tools places an emphasis 
on potency, selectivity, broad profiling and careful controls [12]. Interestingly, proof-of-
target engagement in a relevant cellular model is one requisite for validating a small-
molecule as a high-quality pharmacological tool [12]. This specific requisite can be assessed 
using labelled chemical probes. 
2.2. Labelled chemical probes 
Labelled chemical probes have recently emerged as a powerful tool to investigate and 
characterise ligand-protein interactions in cellular models. In contrast to pharmacological 
tools, less stringent properties are required for labelled chemical probes. However, such 
probes are still required to be suitably potent and selective, and these bioactive molecules 
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additionally must bear ligation handles to perform bioorthogonal reactions with appropriate 
reactive-reporter partners in order to detect the probe-protein complex formed in cells [14].  
Bioorthogonal reactions are particularly attractive in chemical proteomic studies because they 
can take place in cellular systems without interfering with biological processes [15]. These 
reactions have to be fast, compatible under physiological and aqueous conditions, and highly 
selective [16]. It is beyond the scope of this review to give a catalogue and description of all 
existing bioorthogonal reactions, which have already been extensively reviewed [17-19]. In 
addition to the existing bioorthogonal reactions, guidelines to construct new bioorthogonal 
reagents have been suggested to extend the bioorthogonal toolbox [20, 21]. Among the 
twenty unique reactions compliant with the features listed above, two have received 
considerable interest: the strain promoted azide-alkyne cycloaddition (SPAAC) and the 
inverse-electron demand Diels-Alder (IEDDA) reaction [22] (Figure 2). The SPAAC is a 
copper-free variant of the azide-alkyne cycloaddition which is less toxic and therefore more 
compatible with biological environments, whereas the IEDDA is a reaction between a 
strained dienophile and a diene that is sufficiently reactive to proceed at physiological 
temperature and pressure conditions.     
 
Figure 2: SPAAC and IEDDA bioorthogonal reactions 
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The detection of the probe-protein complex can be carried out using different reactive-
reporter partners such as affinity reporters or imaging reporters. Reactive-biotin partners or 
affinity reporters are molecules where the bioorthogonal moiety is attached to biotin. Biotin 
binds to streptavidin and avidin with an extremely high affinity allowing enrichment and 
isolation of the probe-protein complexes by pull-down experiments [23]. The probe-protein 
complex can be then detected by immunoblot analysis. However, such affinity reporters are 
not cell-permeable due to their large size, which precludes performing the detection step in 
living cells. Instead, detection is usually performed on cell lysates or fixed cells. 
Alternatively, reactive-fluorescent partners or imaging reporters are molecules where the 
bioorthogonal moiety is linked to a fluorophore. The probe-protein complex can be visualised 
by in-gel fluorescence analysis and/or by confocal microscopy. Common fluorophores 
employed are cyanine, rhodamine, coumarin and BODIPY dyes. In contrast to the affinity 
reporters, many of the imaging reporters are cell-permeable and therefore they can be applied 
in live cells. 
A promising development of tetrazine-based imaging reporters uses the fluorescence 
quenching effect of tetrazine [24]. Interestingly, the tetrazine moiety which is incorporated to 
perform the bioorthogonal reaction is also able to quench the fluorescence of the fluorophore. 
Therefore, such fluorogenic turn-on reporters increase fluorescence upon the bioorthogonal 
reaction and destruction of the tetrazine functional group. This feature appears to be very 
attractive for in cell imaging, as it reduces the background fluorescence and avoids stringent 
washing cycles, which risk depleting the amount of ligand-target complex when binding of 
the labelled chemical probe is reversible. The first generation of fluorogenic reporters 
(tetrazine-BODIPY with flexible linkers) showed a moderate turn-on ratio of around 10-20-
fold after the IEDDA reaction. By exploiting through-bond energy transfer (TBET) with 
modified linkers, new generations of tetrazine-BODIPY and tetrazine-coumarin have been 
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developed exhibiting 1000-10000-fold fluorescence enhancement after the bioorthogonal 
reaction [25, 26]. Finally, a set of novel fluorogenic tetrazine-based imaging reporters have 
been synthesized to cover the entire emission range from green to far-red [27].  
Table 1 lists the two types of labelled chemical probe / reactive-reporter partner systems that 
have been exploited to carry out target engagement experiments in living systems. They are 
sorted from major to minor changes regarding the structure of the bioactive molecule.  
With bioorthogonal reaction 
Labelled Chemical 
probes 
Recent examples  
(for further examples see Table 3 and 6) 
Reactive-Reporter 
partners 
  
 
Reactive-Fluorescent 
partner 
(imaging reporter) 
 
 
 
Reactive-Biotin partner 
(affinity reporter) 
With a photoreactive and a bioorthogonal groups 
 
 
With a bioorthogonal group 
Legend: 
 
 
Table 1: Enumeration of labelled chemical probe / reactive-reporter partner systems that rely 
on bioorthogonal reactions 
As described in Table 1, the ligand can be functionalised with: 
 a photo-reactive and a bioorthogonal group. The photo-reactive group serves to 
covalently attached the chemical probe to the protein upon UV irradiation [28].  
 a bioorthogonal group.  
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In both cases, the reactive-reporter partner employed for detecting and analysing the probe-
protein complex is an imaging reporter and/or an affinity reporter.  
Not all target engagement experiments involve the use of bioorthogonal reactions. Indeed, the 
use of a labelled chemical probe where the ligand is functionalised with a cell-permeable dye 
to determine target engagement in vitro and in vivo has been recently described [29]. 
Similarly, another bioorthogonal reaction-free system consists of incorporating a 
radiolabelled atom into the structure of the ligand for performing positron emission 
tomography (PET). This approach has been applied preclinically in vivo and translated into 
the clinic. These two labelled chemical probe strategies are summarised in Table 2. 
Without bioorthogonal reaction 
Labelled Chemical 
probes 
Recent examples  
(for further examples see Table 7 to 10) 
Reactive-Reporter 
partners 
 
 
Not required With a cell-permeable dye 
 
 
With a radiolabelled atom 
Legend: 
 
 
Table 2: Enumeration of bioorthogonal reaction-free systems based on two distinct labelled 
chemical probes 
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The systems described in Table 1 and Table 2 have been used to demonstrate that the labelled 
chemical probe engages its intended target in living systems. However, labelling a bioactive 
molecule can change its physicochemical properties and the resulting effect may be different 
to the unlabelled ligand. Hence, competition assays using unlabelled ligands in combination 
with labelled chemical probes have been designed to assess and quantify target occupancy 
across series of related compounds. Such assays depend on the biochemical competition 
between the unlabelled ligand and the probe. Therefore, the labelled chemical probe reports 
only on occupancy at a specific binding site or binding sites that are allosterically coupled to 
it. Target occupancy refers to the measurement of protein directly bound by an unlabelled 
ligand. In the following section, we use selected examples from recent literature to show how 
labelled chemical probes in conjunction with unlabelled ligands are used to demonstrate 
target engagement in living systems and assess target occupancy. 
3. Target occupancy in cells with labelled chemical probes bearing photo-reactive-
bioorthogonal groups 
The first approach described here consists of functionalising a ligand with a photo-reactive 
and a bioorthogonal group. Photo-reactive groups have been largely used for photoaffinity 
labelling (PAL) strategies to identify interactions between bioactive molecules and proteins 
in cells [30]. PAL strategies and the chemistry of photo-reactive groups have been 
extensively reviewed [28, 30, 31]. In short, upon photo-activation, these groups are converted 
into highly reactive intermediates that can covalently bond to the nearest neighbour molecule, 
which ideally is the target protein of the functionalised probe. Benzophenones, aryl azides 
and alkyl diazirines have been widely employed as photo-reactive groups.  
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3.1. Design of chemical probes for PAL 
Once a suitably potent, cell-active and selective ligand has been selected, the sites of 
functionalisation have to be chosen carefully not to disturb the binding of the resulting 
labelled chemical probe to the protein. For that purpose, the bioorthogonal group is 
commonly placed in the solvent exposed region of the ligand. Standard medicinal chemistry 
structure-activity relationships (SARs), crystal structures of ligands bound to target proteins 
or NMR structural studies are useful to identify the solvent exposed regions of particular 
bound ligands. Conversely, due to its photo-crosslinker role, the photo-reactive group has to 
be adequately located to covalently link the probe with its binding protein without impairing 
the probe-protein interaction. Once synthesised, the in vitro potency as well as the cell 
activity of the probes are typically measured on target- and cell-based assays. In parallel, the 
efficiency of the bioorthogonal reaction can be confirmed in vitro (e.g. by LC-MS monitoring 
of reaction progression) to inform on suitable incubation conditions for the target engagement 
experiments.   
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3.2. General workflow for measuring target occupancy in cells with PAL probes 
 
Figure 3: General workflow for measuring target occupancy in cells through labelled 
chemical probes bearing photo-reactive and bioorthogonal groups 
The general workflow for measuring target occupancy in cells with PAL probes is shown in 
Figure 3. Cells are treated with increasing concentrations of the unlabelled ligand of interest 
followed by incubation with the PAL probe at one concentration. After UV-irradiation to 
cross-link the bound probe to its target partner, cells are lysed and bioorthogonal reaction 
with a reactive-reporter partner is performed. An imaging reporter can be used for 
visualisation by SDS-PAGE and in-gel fluorescence (upper panel; Figure 3). An affinity 
reporter can also be used for target enrichment by pull-down with streptavidin followed by 
analysis by immunoblot (lower panel; Figure 3). In either case, quantification of the 
fluorescent band corresponding to the labelled protein of interest reveals a dose-dependent 
decrease in photo-labelling with increasing concentration of the unlabelled ligand due to 
competition for the target binding sites, allowing the in-cell affinity of the ligand to be 
derived. 
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3.3. Recent examples 
References Target 
Inhibitor 
Target occupancy 
assessment 
Labelled chemical probe 
Reactive-Reporter partner 
[32] 
Phospho-
diesterase 
PDE10A 
 
- Competition 
binding assay with 
MP-10 
 
- Fluorescence-based 
analysis with 
TAMRA-azide 
 
- Quantification of 
the fluorescent band 
of PDE10A leads to 
in-cell binding 
affinity 
IC50 = 1.7 M 
 
TAMRA-azide for in gel fluorescence 
analysis 
 
[33] 
-secretase 
(PS1-NTF) 
 
- Competition 
binding assay with 
BMS-163 
 
- Immunoblot-based 
analysis with biotin-
azide 
 
- Quantification of 
the fluorescent band 
of PS1-NTF leads to 
in-cell binding 
affinity 
EC50 = 16 nM 
 
Biotin-azide for pull-down enrichment 
with streptavidin followed by 
immunoblot analysis 
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[34] 
Type 2 
cannabinoid 
receptor 
(CB2R) 
 
- Identification of the 
target protein by 
mass-spectrometry 
based analysis using 
biotin-azide as 
affinity reporter 
 
- Visualisation of the 
target protein by in 
gel fluorescence 
imaging  
 
- FACS analysis used 
for quantification 
where endogenous 
protein is expressed 
at low level 
 
Cy5-azide for in-gel fluorescence 
analysis 
 
 
AlexaFluor647-azide for FACS analysis  
 
Table 3: Recent examples of target occupancy using labelled chemical probes bearing photo-
reactive and bioorthogonal groups. Photo-reactive groups are shown in blue, ligand 
bioorthogonal groups in red and reporter reactive groups in magenta. 
Table 3 highlights three examples where PAL chemical probes have been used to measure the 
occupancy of three distinct targets. The phosphodiesterase PDE10A is a potential target for 
the treatment of Parkinson and Huntington diseases. The clinical candidate MP-10 was used 
as starting point for developing a target occupancy assay [32]. Based on the structure of the 
catalytic domain of PDE10A, positions were identified for the attachment of benzophenone 
photo-reactive group and an alkyne bioorthogonal group without impairing the potency and 
selectivity of the resulting labelled chemical probe, PF-06481942. The potency of PF-
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06481942 was assessed in a phosphodiesterase assay using recombinant enzyme, showing it 
potently inhibited PDE10A (IC50 = 29 nM), comparable to the parent inhibitor MP-10 (IC50 = 
1.26 nM). After establishing the optimal probe concentration (30 nM) and UV-irradiation 
time (20 min) for PDE10A labelling with PF-06481942, the potency and selectivity of MP-10 
for PDE10A in tissue lysates was determined using a competition assay format (MP-10 
concentration range: 0-3 M - IC50 = 4.2 nM). Encouraged by this promising result, the same 
approach was applied to cell cultures, showing that MP-10 engaged its target PDE10A with 
cellular IC50 = 1.7 M. In the cell culture assay, a higher concentration of PDE10A was used 
(1 M) in combination with different concentrations of MP-10 (0-30 M). Interestingly, this 
study also highlighted how the PAL chemical probe revealed that the binding profile of a 
bioactive molecule in native tissues differed from the profile observed using recombinant 
proteins.  
In another example [33], a PAL chemical probe for analysing cellular -secretase was 
developed from the ligand BMS-163. A set of probes was prepared by modifying the 
photoreactive group and the position of the bioorthogonal group. A benzophenone-containing 
probe was able to covalently bind PS1-NTF whereas a diazirine-containing probe was not. It 
was proposed that the reactive carbene generated from the diazirine could be solvent exposed 
and therefore quenched before labelling the protein. This study also illustrated the influence 
of the electronic effect of the benzophenone substituents for the photo-crosslinking step. For 
example, the probe functionalised with a para-nitro benzophenone labelled many off-target 
proteins which were not competed by the ligand BMS-163. In contrast, the probe 
functionalised with para-methoxy benzophenone, having a similar potency in a biochemical 
assay, showed more specific labelling. This suggests a potential difference in the reactivity of 
the two carbenes generated after UV-irradiation leading to differences in the proteins 
labelled. Placement of the alkyne within the probe had a significant impact on the magnitude 
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of the labelling but without changing the in vitro potency. This was rationalised as due to the 
different placement of the alkyne group inducing slightly different binding modes of the 
probe, resulting in distinct alignments of the benzophenone group within the protein and 
therefore modifying the labelling efficiency of the photo-reactive group. Moreover, this 
location change could also influence the efficiency of the bioorthogonal reaction. The 
optimised 163-BP3 probe was used at one concentration (20 nM) to measure target 
occupancy in cultured primary cortical neurons and a dose-dependent decrease in PS1-NTF 
labelling was observed with increasing concentrations of BMS-163 (0-3 M - cell EC50 = 16 
nM).  
In the last of the selected examples, a PAL chemical probe was prepared to investigate the 
type 2 cannabinoid receptor (CB2R) [34]. The ligand LEI101 with selectivity, high solubility 
and oral efficacy in a clinically relevant murine model was chosen as the starting point. After 
identifying the sites of functionalisation based on standard SAR analysis and a docking study, 
the probe LEI121 was synthesised and showed similar potency to the ligand LEI101. 
Membrane preparations from hCB2R-overexpressing CHO cells were treated with 2 M of 
LEI121 and two orthogonal reactive-reporter partners were used to demonstrate target 
engagement of a set of inhibitors tested at one concentration (20 M). An azide-biotin partner 
for affinity enrichment by pull-down experiment with avidin enabled receptor identification 
by mass-spectrometry based analysis, whereas an azide-fluorophore partner allowed 
identification of the interaction between the probe and protein by in-gel fluorescence. This 
analysis led to the detection of two forms of glycosylation of CB2R. Using a competition 
assay format and the imaging reporter, target engagement of several ligands with distinct 
scaffolds was assessed in a concentration range (0-10 M). All compounds displayed a 
concentration-dependent displacement of the probe LE121. Interestingly, the strongest 
diminution in CB2R labelling was observed for the ligand with the lowest IC50 in the 
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biochemical assay. The endogenous CB2R engagement by these ligands was studied in 
human cells using fluorescence-activated cell sorting (FACS) to identify labelled cells. Cells 
treated with 10 M of LEI121 gave a population of cells showing an increase in fluorescence 
which was significantly reduced when the cells were pre-incubated with different 
concentrations of unlabelled ligands (10-20 M). 
Although it is beyond the scope of this review, it is notable that photo-reactivity has been 
successfully coupled with fragment-based drug discovery to carry out the chemical proteomic 
analysis of thousands of reversible fragment-protein interactions in human cells and 
characterise the interactions, allowing further optimisation of these fragments into selective 
ligands [35]. In the same way, photo-reactive groups have also been used to identify new 
drug targets as well as to map the ligand binding sites of several proteins [36, 37]. 
In summary, these PAL chemical probes have been applied with clear success to demonstrate 
direct target engagement and assess target occupancy in cells. The covalent attachment of the 
probe to the target protein after UV-irradiation avoids disruption of the interaction during 
experimental manipulations [32, 33] offering a clear advantage over reversible labelling 
strategies, described in the following sections. However, the use and manipulation of labelled 
chemical probes bearing photo-reactive groups can be restricted compare to the other probes. 
Indeed, due to their chemical and UV-sensitivity, it is not always straightforward to install 
these groups during synthesis. Another consideration is the possibility of cell toxicity when 
longer UV-irradiation times are applied to maximise the cross-linking in cells [32]. 
4. Target occupancy in cells with labelled chemical probes bearing a bioorthogonal 
reactive group 
The second approach focuses on the use of labelled chemical probes only functionalised with 
a bioorthogonal reactive group. Recently, a covalent inhibitor tagged with a bioorthogonal 
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reactive group has been employed to visualise the protein ERK1/2 in cells [38] and to study 
the selectivity of the untagged covalent inhibitor in cells [39]. Although it is beyond the scope 
of this review to comprehensively cover covalent inhibitors, it is worth mentioning that such 
bioorthogonal covalent probes provide a unique opportunity to identify potential cellular off-
targets of the unlabelled covalent inhibitors that could lead to toxicity [40]. 
As mentioned previously, the ligand selected as starting point to develop such probes has to 
be suitably potent and cell active with favourable physicochemical properties. Then, the 
bioorthogonal reactive group has to be positioned appropriately to minimally disrupt the 
probe’s binding at the target. Subsequently, the efficiency of the bioorthogonal reaction can 
be assessed using distinct bioorthogonal partners. Once synthesised and assessed in target- 
and cell-based assays to confirm that the probes are biologically equivalent to their parent 
molecules, the probes can be employed to carry out probe-target co-localisation studies in 
cells. 
4.1. Probe-target co-localisation in cells with labelled chemical probes bearing a 
bioorthogonal reactive group 
The workflow to perform a probe-target co-localisation study is described in Figure 4. Cells 
are treated with the labelled chemical probe at one concentration and incubated with a 
permeable imaging reporter for performing the bioorthogonal reaction inside living cells. If 
the imaging reporter is not cell permeable, fixation and permeabilisation of the cells is 
required before the detection step. Immunofluorescence antibody staining of the protein of 
interest and imaging of the probe–reporter conjugate are enabled by confocal microscopy, 
allowing assessment of the sub-cellular distributions of the labelled chemical probe and the 
target protein, respectively. The merged images highlight the co-localisation of the probe-
target complex in cells (Figure 4). 
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Figure 4: General workflow for assessing probe-target co-localisation in cells 
As an example, one study [41] developed probes for imaging inhibitor binding to the DNA 
damage repair protein PARP1 in cells. The drug molecule olaparib was selected as the 
starting point and a set of probes bearing different bioorthogonal groups was synthesized, all 
of which retained similar potency to olaparib (Table 4). The reactivity of several reactive-
reporter partners in comparison to non-reactive control compounds was investigated because 
side reactions might happen between the reactive-reporter partners and cellular components 
leading to ambiguous results.  No covalent protein binding was observed for most of the 
reactive-reporter partners used, confirming the biorthogonality of the ligation chemistry. 
Each probe was assessed at concentration (2 M) in confocal experiments using the 
appropriate imaging reporter for visualising subcellular location. In order to avoid washing 
out the probe when using a cell-permeable imaging reporter, which can require stringent 
washing procedures to lower the unspecific background staining, the authors chose to fix and 
permeabilise the cells before adding the imaging reporter. Although all three probes studied 
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retained potency in a biochemical PARP1 assay, the use of either SPAAC or CuAAC 
bioorthogonal reactions (systems 2 and 3, respectively; Table 4) led to unspecific staining of 
entire cells when compared to cells treated with DMSO. This unspecific staining was likely 
due to the low efficiency of the bioorthogonal reactions and/or unspecific interactions 
between the imaging reporter and cell components. Interestingly, when the IEDDA reaction 
was used, a specific nuclear staining was observed compared to the staining of cells treated 
with DMSO. The co-localisation of the trans-cyclooctene (TCO)-functionalised probe with 
the target protein PARP1 was assessed by confocal microscopy (Figure 5). This showed that 
the specific nuclear staining observed with TCO-probe / Cy5-Tz system was correlated with 
the cellular localisation of PARP1 staining by anti-PARP1 antibody and Alexa488 
conjugated secondary antibody. 
 
olaparib – pIC50: 8.8 
Labelled chemical probes 
Cellular distribution 
Reactive-reporter partners 
 
TCO-probe – pIC50: 7.5 
  
Cy5-Tetrazine 
IEDDA reaction 
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BCN-probe – pIC50: 7.1 
 
 
TAMRA-azide 
SPAAC reaction 
 
Alykne-probe – pIC50: 8.9 
 
 
TAMRA-azide 
CuAAC reaction 
Table 4: Labelled chemical probe / reactive-reporter partner systems for assessing cellular 
distribution. Bioorthogonal moieties are shown in red for labelled chemical probes and in 
magenta for the reporter partners. Scale bar = 25 m.  Cellular distribution images adapted 
with permission from [41]. Copyright 2016 American Chemical Society 
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Figure 5: Co-localisation of TCO-probe – Cy5-tetraxine conjugate (red) with target protein 
PARP1 (green). Scale bar = 25 m. Adapted with permission from [41]. Copyright 2016 
American Chemical Society 
Similar approaches have been applied to modification of the bioactive molecules MLN8054 
[42], BI2536 [43] and PF04217903 [44] to develop labelled chemical probes for assessing 
their co-localisation in live cells with Aurora kinase A, Polo-like kinase 1 and hepatocyte 
growth factor receptor MET, respectively. 
4.2. General workflow for measuring target occupancy in cells 
The probe-target co-localisation protocol can be adapted to a competition assay format with 
unmodified ligands in order to determine target occupancy in live cells. The general 
workflow for determining target occupancy in cells with the bioorthogonal ligation strategy 
through a competition format is summarised in Figure 6. 
Cells are treated with one concentration of the labelled chemical probe followed by a 
concentration range of the unlabelled ligand.  
• For the affinity reporter analysis (upper panel, Figure 6): after cell lysis, 
bioorthogonal reaction is performed with an affinity reporter coupled to streptavidin beads 
and bound proteins are analysed by immunoblotting. Quantification of the level of protein 
pulled down by the labelled chemical probe shows a dose-dependent decrease in protein 
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enrichment with increasing concentration of the ligand, allowing derivation of the cellular 
binding affinity of the ligand. 
• For the imaging reporter analysis (lower panel; Figure 6): the bioorthogonal reaction 
is performed with an imaging reporter either in live or fixed and permeabilised cells and 
fluorescently labelled protein-probe complex is detected by confocal microscopy. 
Quantification of the fluorescence intensity reveals a dose-dependent reduction in 
fluorescence signal with increasing concentration of the ligand leading to a value for the 
cellular binding affinity of the ligand. 
 
Figure 6: General workflow for measuring target occupancy in cells through the 
bioorthogonal ligation strategy. See Table 1 for key to symbols.  
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4.3. Recent examples 
The first example highlighted here was a continuation of the study previously described  for 
the cellular co-localisation of a TCO-functionalised probe with PARP1 [41]. After 
characterising the cellular distribution of the TCO-probe and assessing the co-localisation of 
the TCO-probe with PARP1, two orthogonal reactive-reporter partners – a tetrazine-biotin as 
an affinity reporter and a tetrazine-fluorophore as an imaging reporter – were used to measure 
PARP1 occupancy in cells (Table 5).   
After optimising the incubation time, the temperature and the probe concentration in cell 
extracts, the TCO-probe was used in an affinity enrichment experiment in HeLa cells with 
biotin-tetrazine as an affinity reporter. Cells were treated with 1 M of TCO-probe and 
different concentrations of olaparib (0-400 nM). Immunoblotting analysis followed by 
quantitative mass spectrometry gave an olaparib dose-dependent reduction in target binding 
of the TCO-probe (pIC50 = 8.8).  
In order to further characterize PARP1 engagement with olaparib in cells, the authors applied 
an orthogonal reactive-reporter partner. Based on the probe-target co-localisation experiment, 
Cy5-tetrazine was selected as an imaging reporter. Similarly to the enrichment assay, cells 
were treated with 1 M of the TCO-probe and a range of concentrations (0-250 nM) of 
olaparib. A concentration-dependent decrease of the fluorescent signal was observed in cells 
by confocal microscopy. Quantification of the fluorescence signal in several nuclei was 
combined to measure the affinity (pIC50 = 9.2). The same TCO-probe was used to measure 
the target occupancy of two other PARP1 inhibitors having distinct scaffolds, rucaparib and 
PJ34. Interestingly, the cellular binding of these inhibitors (rucaparib, pIC50 = 8.8; PJ34, 
pIC50 = 7.0) were lower than that for olaparib, which correlated with the potencies previously 
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obtained in cell lysates. These results highlight the potential for target occupancy assays with 
the same labelled chemical probe to rank and triage distinct inhibitors.  
 
TCO-probe – pIC50 = 7.5 
Reactive-reporter partners Target occupancy result 
 
 
Biotin-tetrazine 
- Immunoblot analysis with 
increasing concentration of 
Olaparib 
 
- Quantification of the fluorescence 
bands 
 
- pIC50 = 8.8 
 
Cy5-tetrazine 
- Fluorescent images with 
increasing concentration of 
Olaparib 
 
- Quantification of the fluorescence 
signal 
 
- pIC50 = 9.2 
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Table 5: PARP1 occupancy measured by bioorthogonal ligation with the TCO-probe and two 
orthogonal reactive-reporter partners. Bioorthogonal groups are shown in red in the TCO-
probe and in magenta in the reactive-reporter partners.  
Finally in this example, fluorescence-activated cell sorting (FACS) was used to measure 
target occupancy in single cells. Although this technology does not give subcellular 
resolution, it has the advantage of high throughput sorting of a cell population receiving a 
particular treatment. Jurkat cells were incubated with 1 M of the TCO-probe and different 
concentrations of olaparib (0-250 nM). After fixation and permeabilisation, cells were treated 
with the Cy5-tetrazine imaging reporter and subjected to flow cytometric analysis. The 
quantification of the number of fluorescent cells gave binding measurements for olaparib, 
rucaparib and PJ34 (pIC50 = 8.8, 8.0 and 7.0, respectively). These values were in agreement 
with those obtained with confocal microscopy analysis in previous experiments.  
The small differences in the estimated cellular binding affinity of olaparib through these three 
competitive experiments using a similar probe but distinct orthogonal reactive-reporter 
partners highlights the robustness of using labelled chemical probes bearing a bioorthogonal 
group to assess target occupancy. Bioorthogonal ligation strategies have been successfully 
applied for other target proteins as summarised in Table 6. 
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Ref Target 
Inhibitor Reactive-Reporter partner 
Target occupancy assessment Labelled chemical probe 
[45] MDM2 
 
 
BODIPY-Fl-tetrazine 
 
- Cellular distribution and probe-target 
co-localisation in fixed and live cells 
 
- High throughput assay coupled with 
high content imaging analysis in a 
competition format to assess target 
occupancy of several inhibitors using 
the same labelled chemical probe / 
imaging reporter system  
[46] MDM2 
 
 
BODIPY-tetrazine 
 
- Cellular distribution and probe-target 
co-localisation in cells with RG7388-
TCO 
 
- Target engagement through a 
competition assay with unlabelled 
RG7388 molecule 
 
- Assessing the protocol sequence by 
modifying the incubation order 
between RG7388-TCO and RG7388   
 
[47] BRD4 
 
 
Biotin-azide 
CuAAC reaction with JQ1-PA 
 
29 
 
 
 
Biotin-tetrazine 
IEDDA reaction with JQ1-TCO 
 
- Assessing gene expression after 
inhibition of BRD4 with enrichment 
experiments using both probes 
 
- Cellular distribution and probe-target 
co-localisation in cells with both probes 
using the appropriate imaging reporters 
 
- Fluorescence cell sorting by FACS 
Table 6: Recent examples of cellular target occupancy measured using bioorthogonal 
ligation. Bioorthogonal groups are shown in red in the labelled chemical probe and in 
magenta in the reactive-reporter partner. 
Inhibitors of the MDM2-p53 protein-protein interaction were studied in a disease-relevant 
cellular model [45]. The subcellular distributions and co-localisation of a set of probes at 
different concentrations (0-16 M) with the MDM2 target were assessed using different 
imaging reporters in fixed and live cells. No significant difference was observed for the 
fluorescent staining between fixed and live cells. A clear correlation between MDM2 
expression and probe-imaging reporter intensity in the nucleus was observed. In parallel, it 
was shown that all probes tested were able to induce increased expression of MDM2 in 
SJSA-1 cells to different extents. The induction of expression of MDM2 protein is a 
consequence of a feedback mechanism through the p53 pathway in response to MDM2 
inhibition. A probe bearing a TCO group was selected to establish a cellular target occupancy 
assay in 384-well plates to identify and rank inhibitors in high throughput. Using high content 
automated imaging analysis at single cell resolution, the cellular binding of several inhibitors 
was measured. This advanced feature opens the door to the introduction of labelled chemical 
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probe strategies earlier in drug discovery programs as a way to triage compounds based on 
their capacity to permeate through the cell membrane and reach their intended target in cells. 
A TCO-probe, RG7388-TCO, was also developed to study the MDM2-p53 protein-protein 
interaction [46]. RG7388-TCO induced increased expression of MDM2 in SJSA-1 cells in a 
dose-dependent manner. To determine the cellular localisation of probe-bound MDM2, the 
turn-on fluorogenic dye, BODIPY-tetrazine, was used as an imaging reporter with enhanced 
signal-to-background ratio. Nuclear MDM2 staining was co-localised with bound RG7388-
TCO – BODIPY-tetrazine conjugate in two MDM2 overexpressing cell lines, SJSA-1 and 
T778. In a competition assay format where cells were treated with 100 nM of RG7388-TCO 
for 1 h followed by incubation for 3 h with different concentrations (100-1000 nM) of 
RG7388 before adding the BODIPY-tetrazine, a reduction in the fluorescence signal with 
increasing concentrations of RG7388 was seen. A 50% reduction in the fluorescence signal 
was induced with 100 nM of RG7388 when compared to the negative control (cells receiving 
DMSO instead of RG7388). Reversing the order of addition of the reagents and treating cells 
with the same concentration range of RG7388 for 1 h followed by incubation with 100 nM of 
RG7388-TCO for 3 h and subsequently addition of BODIPY-tetrazine also showed a dose-
dependent decrease in fluorescence signal, but with a reduction in the magnitude of the 
inhibition. The difference between these protocols highlighted the incubation time- and 
concentration-dependency of MDM2 induction following the inhibition of the MDM2-p53 
interaction. The total incubation time with 100 nM of RG7388-TCO in the first sequence was 
4 h whereas this time was reduced to 3 h in the reverse protocol. Therefore, without RG7388 
treatment, a longer incubation time with RG7388-TCO would induce expression of a larger 
amount of MDM2 protein, resulting in an increase in the fluorescence signal. This study 
highlights the potential for labelled chemical probes to perturb the expression of some target 
proteins in cells, rendering the quantification of the cellular target occupancy sensitive to the 
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assay protocol. Although the MDM2-p53 protein complex is a particular example, it suggests 
an important consideration for experimental designs using labelled chemical probes in order 
to have the highest confidence in the results obtained.   
In another example, two labelled chemical probes bearing distinct bioorthogonal groups were 
used to study the bromodomain-containing protein 4 (BRD4) belonging to the family of 
bromodomain and extraterminal domain (BET) proteins [47]. The two probes, named JQ1-
PA and JQ1-TCO, were biologically equivalent to the parent molecule JQ1 which was used 
as the starting point. 2 M of each probe was combined with an affinity reporter in an 
enrichment experiment to identify genes that were up- and down-regulated upon BET 
inhibition in different cell lines. Distinct binding modes of BRD4 at genes that responded to 
BET inhibition compared to those that did not was suggested to account for the differential 
effects on gene expression. An imaging reporter was used to perform fluorescence 
microscopy and flow cytometry analysis in cultured cells. This demonstrated a clear co-
localisation of the probes with BRD4 protein in cell nuclei. Using the FACS strategy, the 
team revealed an increase in the fluorescent cell population when the cultured cells were 
treated with increasing concentrations of the labelled chemical probes (from 70 nM to 1 M). 
As expected, a decrease in the fluorescent cell population was then observed when cells were 
further incubated with the unlabelled BET inhibitor, JQ1. This study demonstrates the 
potential to combine target localisation and occupancy assays with gene expression analysis 
as a downstream biomarker of target engagement.  
This approach involving labelled chemical probes bearing bioorthogonal reactive groups has 
been successfully applied to assess intracellular target-probe co-localisation, demonstrate 
direct target engagement and measure target occupancy in cells. However, the success of 
such strategies relies on the exposure of the target to the probe, which is highly dependent on 
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the efficiency of the bioorthogonal reaction. Furthermore, this technology has been mainly 
focused on cellular models, where high resolution is necessary and achievable, whereas PET 
imaging (discussed below) can provide assessments of target binding in tissues and whole 
organisms.  
5. Target occupancy in cells with a bioorthogonal reaction-free system 
In the foregoing examples, bioorthogonal reactions were a key element in the target 
engagement experiments. However, this element is not always required. A new approach 
using a labelled chemical probe bearing a cell-permeable dye has been recently described 
[29]. The workflow for measuring target occupancy in cells without using any bioorthogonal 
reaction is summarised in Figure 7. This strategy relies on fluorescence polarisation 
anisotropy, which can differentiate fluorescent small molecules in the free and protein-bound 
states. Following polarised light excitation, small molecules which are bound to a protein 
have a slow rotation allowing them to keep their orientation and emit light retaining the 
incident polarisation. Conversely, small molecules in solution have more freedom and rotate 
quickly, resulting in a depolarisation of the emitted light and thus lower polarisation 
anisotropy. Cells are treated with one concentration of the labelled chemical probe and a 
concentration range of the unlabelled ligand. Quantification of the fluorescence polarisation 
anisotropy signal reveals dose dependent target engagement, with lower anisotropy signal 
detected when a higher concentration of the unlabelled ligand is present. 
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Figure 7: Experimental workflow for measuring target occupancy in cells with a 
bioorthogonal reaction-free strategy based on detection of fluorescence polarisation. See 
Table 1 for key to symbols. 
In the recent paper [29], an irreversible covalent binding drug, ibrutinib, and a reversible 
binding drug, olaparib, were studied. For clarity of comparison with other methods (Section 3 
and 4), we focus here on the results obtained with olaparib. This PARP1 inhibitor was 
functionalised with the cell-permeable fluorophore BODIPY to give the labelled chemical 
probe OlBFL (Table 7). As for the bioorthogonal moieties described earlier, the fluorophore 
had to be suitable positioned in order not to affect ligand binding to the protein. 
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Ref Target 
Inhibitor 
Target occupancy assessment 
Labelled chemical probe 
[29] PARP1 
 
- Defined a parameter (r·int) to 
take into consideration the 
influence of higher OlBFL 
concentrations on the response of 
the anisotropy signal 
 
- Cellular localisation of OlBFL 
 
- Target occupancy measured 
through a competition assay 
format with a concentration range 
of olaparib 
 
 
Table 7: Target occupancy measured without using bioorthogonal reactions. BODIPY 
fluorophore is shown in green. 
In the fluorescence polarisation experiment, the anisotropy signal corresponds to an average 
of all excited labelled chemical probes present in the cells and thus depends on the 
concentration of the labelled chemical probe. This concern was highlighted by the authors, 
implying that at higher OlBFL concentrations there is more unbound OlBFL (because all 
PARP1 binding sites are occupied), leading to a non-specific decrease in the anisotropy 
signal despite high target engagement. To overcome this issue, the study authors derived a 
parameter, r·int, which corresponds to the concentration of OlBFL bound to PARP1. Using 
this metric, the team showed that the r·int value remained constant when higher 
concentrations of OlBFL were employed. The cellular localisation of OlBFL at one 
concentration (500 nM) in HT1080 cells was determined and showed a high anisotropy signal 
in the nucleus where PARP1 is localised. The anisotropy signal was decreased in a dose-
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dependent manner when cells were exposed to increasing concentrations of olaparib (0-1 
M). Through this competition assay, apparent intracellular kD values were determined in 
three cell lines: 1.97 nM in HT1080 (fibrosarcoma), 1.93 nM in HCC1937 (breast cancer) 
and 1.92 nM in MHHES1 (Ewing’s sarcoma).  
In summary, the application of a bioorthogonal reaction-free strategy to measure cellular 
target occupancy is an exciting development. However, due to the necessary size of the 
appended fluorophore, successful extension to other systems may depend on the size and 
intrinsic permeability of the parent ligands, as larger molecular weight labelled chemical 
probes may have limiting cell-permeability. As mentioned previously, the use of PAL 
chemical probes bearing a photo-reactive group and a bioorthogonal group can also be 
restricted by technical considerations. Hence, at present labelled chemical probes bearing 
bioorthogonal groups appear to be the most generally applicable strategy to determine target 
engagement at cellular resolution. 
The approaches described so far involved target occupancy studies in cell lines which are a 
promising starting point for translating knowledge of biochemical affinity to the in vivo 
setting. For drug development, the ideal would be to also assess target occupancy in 
preclinical animal models and ultimately in human patients. In these contexts, positron 
emission tomography (PET) using radiolabelled chemical probe has received particular 
attention.  
6. Positron emitting groups as a probe labelling strategy in preclinical models and 
clinical settings 
Positron emission tomography (PET) is a clinical imaging tool that has been widely applied 
to address key questions in drug development and study drug biodistribution and target 
occupancy [48]. For example, 
18
F-fluorodeoxyglucose (
18
F-FDG), an 
18
F-labelled glucose 
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derivative, has been extensively used as a PET biomarker to assess the function of metabolic 
pathways and diagnose or study cancer [49] and neurodegenerative diseases [50, 51]. These 
PET biomarker probes aim to study biological processes in abnormal disease states and also 
potential changes in response to a therapeutic [52-54]. Here, we focus on the strategy that 
relies on the functionalisation of a bioactive molecule with a radiolabelled atom. Such 
radiolabelled chemical probes, also called radiotracers, have to display a relatively short half-
life in order to allow administration at doses high enough to afford a suitable imaging signal 
without risking patient health through long exposure to ionising radiation [55]. Due to their 
short half-lives, 
11
C (about 20 minutes) and 
18
F (about 110 minutes) are the two most 
frequently employed radiolabelled atoms.  
Typically, the radiolabelled chemical probe is administered in vivo at very low doses. Unlike 
the techniques involving labelled chemical probes previously described, the PET technology 
provides useful information on the biodistribution of radiolabelled chemical probes in tissues, 
but cannot give resolution at the cellular or intracellular scale. Unlabelled ligand (so called 
cold ligand) which competes with the radiotracer can be co-dosed. Quantitative modulation 
of the PET signal following the cold ligand administration over a range of doses allows the 
measurement of target occupancy as a function of ligand concentration in the plasma, leading 
to the in vivo target affinity of the cold drug. Moreover, this in vivo plasma concentration-
target occupancy study facilitates an estimation of the therapeutic index and can guide dose 
selection for clinical trials [56].  
6.1. PET methods for preclinical bio-distribution and target engagement studies in 
vivo 
To allow an easy comparison with the in vitro methods discussed above, the following 
section focuses on the PET method described for the olaparib-PARP1 drug-protein complex. 
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A recent review has covered PARP1 imaging studies using PET with several radiolabelled 
chemical probes [57]. Among the olaparib-based PET labelled probes, [
18
F]PARPi has been 
studied in mouse models of glioblastoma [58] and small-cell lung cancer [59] (Table 8). 
Ref Target 
Olaparib 
In vivo studies 
Radiolabelled chemical probe 
[58] 
PARP1 
 
- [
18
F]PARPi biodistribution 
 
- In vivo (murine) whole body 
imaging without or with pre-
treatment with olaparib (target 
engagement imaging) 
[59] 
 
- [
18
F]PARPi biodistribution 
 
- Assessing potential correlation 
between tumour size and 
[
18
F]PARPi tumour uptake  
 
- In vivo (murine) whole body 
imaging without or with pre-
treatment with 2 drugs (target 
engagement imaging) 
 
- Studying the in vivo kinetics 
of the target engagement event 
for the 2 drugs  
Table 8: Examples of PET imaging using [18F]PARPi radiolabelled chemical probes in two 
mouse models. Radiolabelled atom is shown in orange. 
In one study,  [
18
F]PARPi radioactivity was quantified in several organs 2 hours after dosing 
to a mouse model of glioblastoma [58]. This bio-distribution study showed tumour uptake 
(1.82 % injected dose/g  [%ID/g]), and also that the tumour-to-muscle ratio was 5.1, whereas 
the tumour-to-brain ratio was 54.9. The authors showed that pre-injecting the cold drug 
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olaparib at higher dose reduced the tumour uptake by 87%. Furthermore, significant tracer 
uptake was also identified in the gastrointestinal tract and hepatobiliary system due to the 
rapid clearance of [
18
F]PARPi. PET quantification of uptake into tumours from images 
acquired 2 h post-injection of [
18
F]PARPi showed that mice receiving the radiolabelled 
chemical probe had a radioactivity of 2.15 %ID/g whereas mice treating with the probe and 
olaparib had a reduced radioactivity of 0.28 %ID/g.  
A separate study [59] investigated which image sampling time point after IV dosing of 200-
300 Ci of [18F]PARPi to tumour-bearing mice would provide the highest tumour-to-muscle 
ratio. Imaging at 120 minutes post-dose appeared to be the most suitable time point, where 
0.87 %ID/g tumour uptake was observed while the muscle uptake was 0.12 %ID/g. PARP1 
engagement was explored for two distinct drugs, olaparib and talazoparib, using a 
competition assay. IV administration of either olaparib (0-50 mg/kg) or talazoparib (0-15 
mg/kg) was followed by 200-300 Ci of [18F]PARPi 30 minutes later and PET images were 
then recorded after 2 hours. As expected, both of the drugs were able to block [
18
F]PARPi 
binding, but with different efficacies. For example, at 15 mg/kg, talazoparib and olaparib 
showed 84% and 75% inhibition of the PET signal, respectively. Subsequently, the on-target 
residence time of the two drugs was studied by varying the time (1 to 48 hours) between the 
injection of the cold drug and the radiolabelled chemical probe. The doses (olaparib, 50 
mg/kg; talazoparib, 0.3 mg/kg) of the drugs and the dose of the PET probe were kept constant 
for all the time points evaluated (1, 2, 4, 8, 24 and 48 hours). By plotting the percentage of 
[
18
F]PARPi signal inhibited for each time point post drug administration, the time taken to 
reduce the [
18
F]PARPi signal in tumour by half was determined as 9.4 h and 9.8 h for 
olaparib and talazoparib, respectively. Interestingly, although these two drugs displayed 
differences in affinity and target engagement, their on-target residence times appeared to be 
similar. 
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These two case studies highlight the use of a radiolabelled chemical probe, developed from a 
known drug, to perform a bio-distribution study and quantify target engagement of several 
inhibitors in animal models. Interestingly, the second study showed that this approach is 
sensitive enough to differentiate partial and complete target engagement. Detection of partial 
target engagement for a drug candidate with such an approach might usefully guide 
adjustments of the dose. Finally, the preclinical characterisation of the in vivo kinetics of 
target engagement can also be assessed by this non-invasive approach. 
6.2. PET methods for clinical biodistribution and target engagement studies  
Rucaparib is a PARP inhibitor which is FDA approved. Recently, a first-in-human study has 
been developed for the rucaparib-based radiolabelled chemical probe named [
18
F]-
Fluorthanatrace or [
18
F]-FTT [60] (NCT02469129 - Table 9). The biodistribution of [
18
F]-
FTT in healthy volunteers as well as in patients with cancer was compared at several time 
points [60]. PET imaging revealed high liver uptake, indicating that the primary route of 
elimination was through the hepatobiliary system. Moreover, one patient with pancreatic 
carcinoma and one patient with hepatocellular carcinoma showed [
18
F]-FTT tumour uptake 
compared to the background tissue activity. It has been clinically shown that PARP inhibitors 
may offer treatment for patients with pancreatic cancer who have failed gemcitabine therapy 
[61], while sensitivity to PARP inhibition has been reported for mouse models of 
hepatocellular carcinoma [62].  
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Ref Target 
Rucaparib 
Clinical study 
Radiolabelled chemical probe 
[60] PARP1  
- Biodistribution and 
organ uptake of the [
18
F]-
FTT in healthy volunteers 
 
- Assessing tumour 
uptake of [
18
F]-FTT for 
patients with cancer 
 
Table 9: First-in-human study of the radiolabelled chemical probe [
18
F]-FTT. Radiolabelled 
atom is shown in orange. 
The radiolabelled chemical probe [
11
C]T-773 was studied as a tool to measure PDE10A 
occupancy by the clinical candidate TAK-063 in healthy subjects [63] (Table 10). The brain 
penetration and distribution of [
11
C]T-773 were determined, then the PDE10A occupancy of 
TAK-063 in relation to its plasma concentration was measured by quantifying the 
displacement of the radiolabelled chemical probe. For that purpose, TAK-063 was orally 
administrated and after either 3 hours or 23 hours, [
11
C]T-773 was administered (IV bolus) 
and PET imaging was performed. Dose dependent target occupancy was seen for TAK-063 
after this single dose. At the 3 hour time point, the occupancy increased from 2.8% for a 3 mg 
dose to 72.1% for a 1000 mg dose. Furthermore, this increase in PDE10A occupancy was 
correlated with an increase in TAK-063 plasma concentration. 
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Ref Target 
TAK-063 
Clinical study 
Radiolabelled chemical probe 
[63] PDE10A  
- Evaluation of the 
penetration and 
distribution of [
11
C]T-773 
in the human brain 
 
- Clinical PDE10A 
occupancy for TAK-063 
through competition 
format assay with [
11
C]T-
773 
 
Table 10: PDE10A occupancy study in healthy subjects with the radiolabelled chemical 
probe. Radiolabelled atom is shown in orange. 
Similar radiolabelled chemical probes demonstrating drug plasma concentration-dependent 
target occupancy have been recently described for other central nervous system diseases [64, 
65]. 
The PET technology has been widely used to assess the biodistribution of radiolabelled 
chemical probes in tissues which is not feasible with the previously discussed fluorescence-
labelled chemical probes. Moreover, such radiolabelled chemical probes have been applied 
with success to evaluate the degree of target occupancy in animal models and in humans. 
These features display some advantages over the use of labelled chemical probes which are of 
more applicability to cellular systems, especially when high resolution or information on 
intracellular location is required. Also, specific facilities are required to carry out 
radiolabelling synthesis and experiments which can be a limitation of this technology. 
7. Summary 
In summary, this review has highlighted through selected recent examples the use of labelled 
chemical probes to determine target engagement in living systems. Such efficient and robust 
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chemical tools can provide key data concerning the ligand-protein interaction in a 
quantifiable manner in cellular models.  Through the use of established methodology for 
PET-radiolabelled chemical probes, this quantitative approach can be extended to animal 
models and human clinical trials. This is of significance, since there remains a need for the 
development and wider application of methods to demonstrate on-target occupancy in 
preclinical drug discovery.  
 A persuasive example of the potential benefit of introducing target engagement experiments 
earlier in drug discovery is provided by the example of iniparib, which was initially 
developed as a PARP inhibitor but failed to show efficacy in a phase III clinical trial. It was 
subsequently shown that iniparib did not bind and inhibit PARP at clinically relevant active 
drug doses [66]. Recently, a comparative study of PARP inhibitors using the labelled 
chemical probe PARPi-FL (also known as OlBFL) demonstrated the inability of iniparib to 
block the binding of the probe to PARP in cells, in contrast to a range of other PARP 
inhibitors including approved clinical agents [59]. Such a result underlines the benefit of 
using labelled chemical probes in the decision-making process to potentially reduce failures 
in preclinical, or even clinical, studies due to insufficient interaction of drug candidates to 
their intended cellular targets.   
The multiple potential uses of (radio) labelled chemical probes is illustrated in Figure 8. 
Labelled chemical probes, developed from suitably potent and selective ligands discovered 
for a target, can be employed to identify potential off-target effect(s), assess intracellular 
distribution, measure cellular target occupancy, and link the on-target pharmacology of the 
ligand to the observed biological effects. Once established, a given labelled chemical probe 
can be used as a screening tool to evaluate the cellular target occupancy of other ligands 
binding at the same target site and to prioritise them for further optimisation. Radiolabelled 
chemical probes, particularly [
18
F]-PET probes, may be more appropriate for studies in 
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animal models. They can help define ligand bio-distribution in animal models, quantify the 
relationship between target occupancy and plasma concentration to inform on the therapeutic 
window, and ultimately guide dose selection for clinical trials. Because labelled chemical 
probes can report at single cell resolution over whole cell populations, whereas radiolabelled 
chemical probes focus on body compartment resolution, these complementary approaches 
appear to be adequate and suitable tools for translational studies from cells to animals. 
 
 
Figure 8: The potential uses of labelled and radiolabelled chemical probes in preclinical drug 
discovery. 
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8. Future prospects 
8.1. Transferring labelled chemical probe technologies from cell lines to animal models 
As mentioned and highlighted with recent examples throughout Sections 3 to 5, labelled 
chemical probes have been mainly employed in cell lines to investigate target engagement. 
However, for translational research, there is a real need to transfer these technologies from 
the cellular context to more sophisticated animal models. While radiolabelled chemical 
probes associated with PET methodologies have been successfully applied to animal models, 
these typically require specialist facilities in terms of radiochemistry, radioimaging and 
analysis that can limit the accessibility of the approach.  
Among the various non-radioactive labelled chemical probes described in this review, two 
have been studied in vivo: namely, the labelled chemical probe JQ1-TCO bearing a 
bioorthogonal group [47] and the labelled chemical probe OlBFL functionalised with the cell-
permeable fluorophore BODIPY [29]. For JQ1-TCO, [47], in vivo administration followed 
by ex vivo bioorthogonal reaction and FACS analysis enabled the probe distribution across 
different tissues between healthy mice and tumour-bearing mice to be studied. For OlBFL 
[29], dorsal window chambers and intravital microscopy, coupled with local administration 
of the drug, enabled target occupancy to be studied  in vivo. However, these rely on ex vivo 
analysis or require particular surgical techniques which may limit applicability and further 
advances in this area are still required. 
8.2. Raman and fluorescence spectroscopy  
Alternatively to the (radio)labelled chemical probes, Raman spectroscopy, which observes 
the specific vibrational and rotational modes characteristic of a given small molecule, has 
been applied recently as a label-free imaging method to study the distribution and metabolism 
pathway of the tyrosine kinase inhibitor Neratinib in cancer cells [67]. As a result, applying 
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this strategy to determine target engagement in cells is potentially feasible and should be 
observed in the near future. 
In addition to this emergent technology, fluorescence spectroscopy involving the use of 
fluorescent probes has received a considerable interest in medical imaging and diagnosis 
[68]. Probes with a UV absorption/emission profile in the near-infrared (NIR) allowing tissue 
penetration have been particularly attractive to study biological processes occurring in animal 
models. Engineered NIR fluorescent probes have been recently used as imaging biomarkers 
to monitor changes related to the balance of reactive oxygen species during injuries in living 
cells and animal models [69-71]. In a similar way, another engineered NIR fluorescent probe 
derived from the epidermal growth factor inhibitor gefitinib has been used as theranostic 
biomarker agent in lung cancer therapy [72]. These NIR fluorescent probes are useful tools 
allowing for diagnosis and treatment efficacy monitoring in animal models and should be 
employed more often in the near future as a complementary tool to the (radio)labelled 
chemical probes in drug discovery programs.     
8.3. Impact of protein degradation strategies on determining target engagement 
Strategies for the pharmacological control of protein degradation by modulating the 
ubiquitin-proteasome system have become of great current interest  [73]. One exciting protein 
degradation methodology uses heterobifunctional molecules (of which the proteolysis 
targeting chimeras (PROTACs) are the most well-known) that contain separate affinity 
groups for an E3-ubiquitin ligase and a target protein of interest and can trigger the 
degradation of the protein of interest through its ubiquitination. The interaction between the 
target protein and the heterobifunctional molecule induces spatial proximity of the target with 
the E3 ligase complex, allowing poly-ubiquitination of the protein and thereby degradation of 
the protein via the proteasome. 
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This approach has been recently used to investigate the in-cell target engagement of a pirin 
inhibitor [74]. A heterobifunctional molecule was constructed containing the pirin-binding 
ligand and a thalidomide analogue to recruit the cullin4-cereblon E3 ligase complex. The 
heterobifunctional molecule showed a depletion of the pirin protein in a dose dependent 
manner. Pirin expression was rescued when cells were pre-treated with an unmodified pirin 
inhibitor prior to adding the probe. Thus targeted degradation can act as readout for 
assessment of target engagement in a competition format. The properties of such 
heterobifunctional molecules might appear to be a potential drawback since they typically 
exhibit high molecular weight and high polar surface area that may limit cell permeability.  
However, the effectiveness of  bioorthogonal reactions for forming the heterobifunctional 
molecule inside the cells from smaller, more cell permeable components has recently been 
demonstrated [75]. Two target proteins BRD4 and ERK1/2 were assessed through such an 
approach using so-called CLIPTACs (click-formed proteolysis targeting chimeras). A 
concentration-dependent degradation of both target proteins in cells was achieved using 
TCO-based chemical probes for the target proteins and a tetrazine-based cereblon-recruiter as 
the E3-ubiquitin ligase partner. 
By combining approaches using different reporter partners to react in cells with the same 
primed target protein probe, a platform of orthogonal readouts can be envisaged to build 
confidence in the target engagement event in cells (Figure 9). This idea was realised when the 
same chemical probe [TCO-probe] was used with an affinity reporter [biotin-tetrazine] and an 
imaging reporter [Cy5-tetrazine] to study the target engagement of olaparib [41]. Extending 
this approach to incorporate the CLIPTAC strategy [75] could offer an efficient general 
platform to investigate target engagement in cells using multiple orthogonal readouts.  
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Figure 9: An efficient general platform for parallel investigations of target engagement in 
cells using multiple approaches. 
As highlighted in Figure 9, a single, well designed labelled chemical probe bearing a 
bioorthogonal group can be employed in cells with a range of reactive-reporter partners such 
as an affinity reporter for protein enrichment experiments, an imaging reporter for protein 
visualisation and/or cell sorting experiments and an E3-ubiquitin ligase recruiter for protein 
depletion experiments. All of these probe-reporter pairs can be adapted to target occupancy 
assays by co-treating cells with competitive unlabelled ligand(s), allowing the cellular 
binding parameters of multiple ligands to be measured. 
9. Future perspective 
Cellular target engagement experiments can answer a central question: does the compound 
reach and associate with its intended target protein in cells? Target occupancy measurements 
allow the subsequent question to be addressed:  is the association sufficient to account for the 
observed biological effects? When combined with quantitative approaches for measuring the 
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intracellular bioavailability of a ligand of interest [76], these techniques can provide 
confidence in the mechanism and specificity of a bioactive molecule, and the tractability of a 
target pathway for drug development. 
Therefore, we can speculate that in a near future (radio) labelled chemical probes will be used 
more routinely in both early and late preclinical drug discovery programs. In early preclinical 
drug discovery, such technologies will be useful not only to assess the direct binding of a 
ligand to its intended target protein at cellular resolution, but also to compare the in cell target 
affinity of ligands having the same target protein to prioritise them for further optimisation. 
In a late preclinical drug discovery, the mechanism of advanced ligands will be confirmed 
through these technologies which can help in the decision-making process and selection of 
candidates. 
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Executive Summary 
Target engagement 
 Target engagement experiments refer to the study of the direct binding of a ligand to 
its intended target protein in living systems. 
 (Radio) labelled chemical probes are the key actors to carry out such experiments.  
Target engagement experiments that rely on the ligation strategy 
 These experiments involve labelled chemical probes and distinct reactive-reporter 
partners that are assembled together in cells using bioorthogonal ligation strategies. 
 Unlabelled ligand is commonly used in combination with the labelled probe to 
measure target occupancy and cellular binding affinity through a competition assay 
format. 
Target engagement experiments that rely on ligation-free strategies 
 Labelled chemical probes functionalised with a cell-permeable dye or radiolabelled 
chemical probe functionalised with a radiolabelled atom are suitable for target 
engagement experiments. 
 Positron emission tomography imaging of biodistribution and target engagement in 
tissues using radiolabelled chemical probes is clinically applicable. 
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